Intravenous Cyclophosphamide for Systemic Sclerosis-Related Lung Disease
Author Information
Author(s): Simeón-Aznar C.P, Fonollosa-Plá V, Tolosa-Vilella C, Selva-O´Callaghan A, Solans-Laqué R, Palliza E, Muñoz X, Vilardell-Tarrés M
Primary Institution: Vall d´Hebron Hospital, Autonomous University of Barcelona
Hypothesis
The study investigates the effectiveness of intravenous cyclophosphamide pulse therapy in treating systemic sclerosis-related interstitial lung disease.
Conclusion
Intravenous cyclophosphamide pulse therapy may stabilize lung function in patients with systemic sclerosis-related interstitial lung disease during treatment and for a median of 26.5 months afterward.
Supporting Evidence
- 8 out of 10 patients showed clinical improvement after treatment.
- The median forced vital capacity (FVC) remained stable during the study.
- Only one patient experienced significant deterioration in lung function.
- The follow-up period after treatment withdrawal averaged 26.5 months.
Takeaway
This study looked at how a medicine called cyclophosphamide can help people with lung problems caused by a disease called systemic sclerosis. It found that the treatment can help keep their lungs stable for a long time.
Methodology
A prospective observational study where ten patients received intravenous cyclophosphamide treatment and were monitored with pulmonary function tests and chest HRCT over 24 months.
Limitations
The study had a small sample size and was conducted at a single center, which may limit the generalizability of the findings.
Participant Demographics
The study included 10 patients (9 women and 1 man) with a median age of 49.8 years, all non-smokers, with varying durations of systemic sclerosis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website